Abstract:Abstract Bladder cancer remains a leading cause of cancer death worldwide and is associated with substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare system. Gross hematuria frequently precedes the diagnosis of bladder cancer. Non-muscle-invasive bladder cancer (NMIBC) is managed initially with transurethral resection of a bladder tumor (TURBT), followed by a risk stratified approach to adjuvant intravesical therapy (IVe), and is associated with an overall survival of 90%. However, cure rates remain lower for muscle invasive bladder cancer (MIBC) owing to a variety of factors. NMIBC and MIBC groupings are heterogeneous and have unique pathological and molecular characteristics. Indeed, The Cancer Genome Atlas project identified genetic drivers and luminal and basal molecular subtypes of MIBC with distinct treatment responses. For NMIBC, IVe immunotherapy (primarily BCG) is the gold standard treatment for high grade and high risk NMIBC to reduce or prevent both recurrence and progression after initial TURBT; novel trials incorporate immune checkpoint inhibitors. IVe gene therapy and combination IVe chemotherapy have recently been completed, with promising results. For localized MIBC, essential goals are improving care and reducing morbidity following cystectomy or bladder preserving strategies. In metastatic disease, advances in understanding of the genomic landscape and tumor microenvironment have led to the implementation of immune checkpoint inhibitors, targeted treatments, and antibody-drug conjugates. Defining better selection criteria to identify the patients most likely to benefit from a specific treatment is an urgent need.
What problem does this paper attempt to address?
This paper attempts to address the diagnosis and treatment of bladder cancer, especially the latest progress in non - muscle - invasive bladder cancer (NMIBC) and muscle - invasive bladder cancer (MIBC). Specifically, the paper focuses on the following aspects:
1. **Epidemiology and Risk Factors**:
- Bladder cancer is one of the common cancers worldwide, which has a significant impact on patients' quality of life, morbidity, mortality, and the cost of the medical system.
- The paper explores the risk factors of bladder cancer, such as smoking, occupational exposure (rubber, diesel, dyes, etc.), drinking water pollution (arsenic or pesticides), and the impact of specific chemotherapy or radiotherapy regimens.
2. **Pathophysiology and Molecular Mechanisms**:
- It expounds that bladder cancer develops through two different pathways: non - muscle - invasive bladder cancer (NMIBC) and muscle - invasive bladder cancer (MIBC). These two subtypes have unique clinical and pathological features and different molecular properties.
- NMIBC is usually characterized by genomic stability, often with chromosome 9 deletion and FGFR3 mutation; while MIBC involves the loss of function of multiple tumor suppressor genes (such as TP53, RB1, PTEN), accompanied by extensive DNA methylation and histone methylation changes.
3. **Diagnostic Methods**:
- It emphasizes cystoscopy as the gold standard for the initial diagnosis of bladder cancer.
- It explores the application of enhanced diagnostic techniques, such as narrow - band imaging (NBI) and blue - light fluorescence cystoscopy, which improve the ability to detect tumor lesions and reduce the recurrence rate.
- It mentions the application and limitations of urine cytology and other FDA - approved molecular biomarkers in the diagnosis of primary and recurrent bladder cancer.
4. **Risk Stratification and Management Strategies**:
- NMIBC patients are divided into low -, medium -, and high - risk groups according to factors such as the number, size, recurrence rate, stage of the tumor, and the presence or absence of carcinoma in situ (CIS), to guide the treatment after the initial transurethral resection of bladder tumor (TURBT).
- For high - risk NMIBC, Bacillus Calmette - Guérin (BCG) immunotherapy is recommended as the main adjuvant treatment method to reduce or prevent recurrence and progression.
- In MIBC, the importance of radical cystectomy or bladder - sparing strategies is emphasized, and the role of neoadjuvant or adjuvant systemic chemotherapy is discussed.
5. **New Treatment Methods**:
- The paper summarizes the breakthroughs in the field of bladder cancer treatment in recent years, including the application of emerging therapies such as antibody - drug conjugates (ADCs), targeted therapy, and immune checkpoint inhibitors.
- It specifically points out that for metastatic bladder cancer, the introduction of immune checkpoint inhibitors, targeted therapy, and ADCs represents a shift in the treatment paradigm, significantly improving patients' quality of life and prognosis.
In conclusion, this paper aims to provide medical professionals and scientists with a comprehensive overview of the current management and future development directions of bladder cancer, covering all aspects from basic research to clinical practice.